

ThromboGenics and BioInvent Win “Licensing Deal of the Year” at the Scrip Awards 2009

Strategic partnership with Roche for novel anti-cancer antibody TB-403 (anti-PIGF) recognised in award

Leuven, Belgium – 19 November, 2009 – ThromboGenics NV (Euronext Brussels: THR) and BioInvent International (OMXS: BINV) announce today that they won “Licensing Deal of the Year” at the Scrip Awards 2009, presented last night. The award recognises the major partnership deal that ThromboGenics and BioInvent signed with Roche for their novel anti-cancer monoclonal antibody TB-403 (anti-PIGF). It acknowledges the achievement of both companies in crafting a licensing deal that has both monetary and strategic benefits to all parties.

The Scrip Awards are one of the biotech and pharmaceutical industry’s most prestigious and highly contested international awards, and they are chosen by a panel of senior executives from the biotech and pharma industry.

Under the terms of the deal with Roche, ThromboGenics and its co-development partner BioInvent received an upfront payment of €50 million, with an additional €450 million in potential milestones, as well as double digit royalties on future product sales. The working relationship with Roche is continuing to progress well and recently ThromboGenics and BioInvent announced positive results in a Phase Ib trial of TB-403 in patients with advanced solid tumours. The results showed positive safety and tolerability data. ThromboGenics, who discovered TB-403, receives 60% and BioInvent 40% of all revenue from the deal.

Patrik De Haes, CEO of ThromboGenics, commented, “We are delighted to have won the Licensing Deal of the Year at this prestigious awards event. The revenue from the TB-403 deal with Roche has enabled us to concentrate on our strategy to transform ThromboGenics into a successful integrated Company focused on cutting-edge ophthalmic medicines. ThromboGenics continues to go from strength to strength, and the award is a testament to our dedication to novel science. It highlights the significant achievements and progress the Company has made since its conception. We look forward to an exciting year ahead, when the results from our Phase III study for microplasmin will be presented.”

Svein Mathisen, CEO of BioInvent, also commented, “Our co-development agreement with ThromboGenics, which resulted in the deal with Roche, has been extremely productive and positive, and we are pleased that this has been recognised by our peers through this award. The deal has strengthened BioInvent’s financial position, and together with revenues from other collaborations has enabled us to rapidly progress our in-house antibody development programmes. We will continue to benefit from having secured a partner of such high calibre for one of our key programmes. The success of this deal also underlines our strengths as an antibody development company, which is reflected in the deals we have continued to secure both for our antibody discovery platform and our development and manufacturing capabilities.”

-Ends-

For further information, please contact:

ThromboGenics NV

Patrik De Haes, MD
Chief Executive Officer
Tel : +32 (0) 16 75 13 10
E-mail: patrik.dehaes@thrombogenics.com

Stuart Laermer
Chief Business Officer
Tel: +1 (212) 201-0920
E-mail: stuart.laermer@thrombogenics.com

Citigate Dewe Rogerson

Amber Bielecka, David Dible, Nina Enegren
Tel: +44 (0) 207 638 95 71
E-mail: amber.bielecka@citigatedr.co.uk

BioInvent International AB

Svein Mathisen
President & CEO
Tel: +46 (0) 46-286 85 67
Mobile: +46 (0) 708-97 82 13
E-mail: svein.mathisen@bioinvent.com

Cristina Glad
Executive Vice President
Tel: +46 (0) 46-286 85 51
Mobile: +46 (0) 708-16 85 70
E-mail: cristina.glad@bioinvent.com

College Hill (media enquiries)

Holly Griffiths, Sue Charles, John McIntyre
Tel: +44 (0) 20 7866 7856
E-mail: bioinvent@collegehill.com

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PIGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abelló, Bayer HealthCare, ImmunoGen, Mitsubishi Tanabe Pharma



Corporation, OrbusNeich, UCB and XOMA. More information is available at www.bioinvent.com.

About Scrip World Pharmaceutical News

Scrip World Pharmaceutical News was established in 1972 and – since that time – has continued to serve as the leading news and information source for the world’s pharmaceutical and biotech industries. Scrip’s experienced team of writers, analysts and editors provide the latest news, features and commentary from around the globe. Scrip is published by Informa Business Information, a division of Informa plc, and the leading global provider of specialist information to the scientific, academic and medical communities.

ThromboGenics NV

Gaston Geenslaan 1
B-3001 Leuven
Belgium
Tel: +32 (0) 16 75 13 10
www.thrombogenics.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263,
Address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Tel: +46 (0) 46 286 85 50
info@bioinvent.com
www.bioinvent.com

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.